Analyst Price Target is $78.78
▲ +51.61% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Intra-Cellular Therapies in the last 3 months. The average price target is $78.78, with a high forecast of $98.00 and a low forecast of $62.00. The average price target represents a 51.61% upside from the last price of $51.96.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in Intra-Cellular Therapies. This Buy consensus rating has held steady for over two years.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.